Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced an amendment to its collaboration with Takeda Pharmaceutical, discontinuing the discovery component while maintaining options for late-stage CNS programs. Takeda will pay Wave $22.5 million for related expenses. This change enables Wave to advance CNS programs independently, excluding three specified targets. Ongoing clinical trials for WVE-004 and WVE-003 are unaffected. Wave's cash runway remains stable, expected to fund operations into Q2 2023, bolstering investor confidence in the company's strategic direction.
Wave Life Sciences has announced the initiation of a Phase 1b/2a clinical trial for WVE-N531, targeting Duchenne muscular dystrophy (DMD) in boys amenable to exon 53 skipping. This candidate is notable for utilizing a novel PN backbone chemistry. Preclinical data revealed a significant increase in dystrophin production and survival rates in animal models. The study aims to evaluate safety, pharmacokinetics, and pharmacodynamics in 15 participants aged 5 to 12 years. Clinical data from this trial is expected to inform future development decisions throughout 2022.
Wave Life Sciences (WVE) presented promising preclinical data on its ADAR-mediated RNA editing capabilities at the 2021 Analyst and Investor Research Webcast. Key highlights include:
- Editing levels in CNS tissues sustained for at least four months.
- Four-fold increase in serum AAT protein restoration over control, with 85% identified as functional M-AAT.
- Application in AAT deficiency treatment shows durable restoration of M-AAT protein.
These advancements demonstrate Wave's leadership in RNA editing, with ongoing studies to enhance therapeutic applications across multiple diseases.
Wave Life Sciences (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will participate in a fireside chat at the Chardan Virtual Genetic Medicines Conference on October 4, 2021, at 2:00 p.m. ET. A live webcast of the event will be available on the company’s Investor Relations page, and a replay will be archived for a limited time after the presentation. Wave Life Sciences focuses on developing treatments for devastating diseases using its PRISM platform, aiming for patient-focused solutions.
Wave Life Sciences has initiated dosing in its Phase 1b/2a SELECT-HD trial for WVE-003, aimed at treating Huntington's disease (HD). This investigational therapy specifically targets the mutant huntingtin protein while preserving the wild-type protein. The SELECT-HD trial is designed as global, multicenter, and placebo-controlled, expecting to enroll 36 patients. Preclinical data indicate WVE-003 demonstrates selective potency and durability, which are critical for clinical success in HD. Results are anticipated in 2022, with findings to be presented at the EHDN 2021 Remote Meeting.
Wave Life Sciences (Nasdaq: WVE) announced an upcoming analyst and investor research webcast on September 28, 2021, at 10:00 a.m. EDT. The event will showcase the company’s advances in ADAR-mediated RNA editing, particularly its alpha-1 antitrypsin deficiency (AATD) program, along with updates on its preclinical neurology portfolio and PRISM™ platform. Presentations will review data from the TIDES USA and Oligonucleotide Therapeutics Society meetings. Registration and live webcasts will be accessible on Wave's investor relations website.
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The pre-recorded presentation will be available for on-demand viewing starting September 13, 2021, at 7:00 a.m. ET. Interested viewers can access the webcast on the company's Investor Relations page and it will be archived for 90 days post-event. Wave Life Sciences focuses on developing innovative treatments for genetically defined diseases using its proprietary PRISM platform.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced it will present nine findings at TIDES USA and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS). These conferences will showcase advancements in ADAR-mediated RNA editing and the PRISM™ platform. Significant presentations include enhancing pharmacologic profiles of CNS-targeted therapies and a program for alpha-1 antitrypsin deficiency. The events will occur from September 20-29, 2021, further emphasizing Wave's commitment to developing precise treatments for genetically defined diseases.
Wave Life Sciences (WVE) has initiated the FOCUS-C9 clinical trial for WVE-004, targeting C9orf72-associated ALS and FTD. The company reported a net loss of $38.8 million for Q2 2021, slightly down from $40.5 million in Q2 2020. R&D expenses remained stable at $31.6 million. A notable highlight includes proof-of-concept data showcasing over 90% knockdown of polyGP proteins. Wave anticipates generating significant clinical data through 2022 and aims to utilize its PRISM platform for advancements in various genetic diseases. Cash and equivalents totaled $143.8 million as of June 30, 2021.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced a live webcast on August 5, 2021, at 8:30 a.m. ET to discuss its Q2 2021 financial results alongside a business update. The call will be accessible via the Investor Relations page on their website or by phone using specific dial-in numbers. The company focuses on developing genetic medicines and aims to deliver best-in-class treatments for genetically defined diseases using its proprietary PRISM platform. For more information, visit Wave's website.